Pneumococcal Vaccines Market By Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine), By Product Type (10-Valent PCV, 13-valent PCV, 23-valent PPSV) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026
Industry Outlook
The global pneumococcal vaccines market held US$ 7,108.7 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 5.1% during the forecast period from 2018 to 2026. Pneumococcal diseases are one of the leading cause of serious illness globally resulting in high number of hospitalization every year. Diseases caused by pneumococcus bacteria include pneumonia, otitis media, sinus, meningitis and sepsis. According to National Foundation of Infectious Diseases (NFID), more than one million adults in the U.S. suffer from pneumococcal pneumonia every year and close to half a million people hospitalizations occur annually in the United States. The burden of pneumococcal diseases is higher in children below 5 years old and adults above 65 years. Developing countries are the most affected by pneumococcal diseases, for instance, India holds the highest number of global pneumonia deaths, accounting for 20 percent of worldwide pneumonia deaths in children below the age of 5. However, constant initiatives by government across the world and private health organizations there has been significant reduction in number deaths occurring, especially in the developing countries.
The market players operating in the market are focusing on low income countries and developing countries by investing and partnering with local players to maintain the supply of vaccines in the region. North America held the largest share in the global pneumococcal vaccines market owing to the domicile of two major pneumococcal vaccines producers (Pfizer, Inc. and Merck & Co., Inc.) in the region. Pneumococcal conjugate vaccines produced by these pharma giants is part of the routine vaccine program in the U.S. and Canada. Asia Pacific and Latin America are projected to witness significant growth during the forecast period owing to high burden of pneumococcal diseases in the region and supportive government policies rendering market growth.
"13-valent PCV Set to Drive the Market of Pneumococcal Vaccines Market"
In 2017, 13-valent PCV vaccine held the largest share in the global pneumococcal vaccines market. PVC13 offers a significant benefit for preventing pneumonia and invasive diseases caused by Streptococcus pneumonia in adults and children. The Centers for Disease Control and Prevention (CDC) PCV13 vaccines for children below 2 and adults above 65 years of age. Moreover, it is now recommended that adults above 65 and older to get both PCV13 and PPSV23 vaccine for better immunogenicity against various serotypes of pneumococcus. Moreover, Pfizer’s 20-valent PCV and Merck’s 15-valent PCV are in the late stage of the clinical trials and expected to enter the market during the forecast period, which will further provide thrust to pneumococcal market.
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.
Market is studied in order to understand the current dynamics and future trends in the global pneumococcal vaccines market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in pneumococcal vaccines market include Pfizer, Inc., Merck & Co., Inc. and GlaxoSmithKline plc.
Key questions answered in this report
- How the global pneumococcal vaccines market will perform during the forecast period from 2018 to 2026?
- What are the latest trends in the pneumococcal vaccines market and valuable opportunities for key players?
- Who are the leading players in the global pneumococcal vaccines market?
- Which is the leading/and fastest region in the global pneumococcal vaccines market?
- What are drivers and restrains governing the global pneumococcal vaccines market?
- What is the epidemiology of pneumococcal diseases worldwide?
- How is the pipeline of the pneumococcal vaccines?
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global PV Market Portraiture
2.2. Global PV Market, by Vaccine Type, 2017 (US$ Mn)
2.3. Global PV Market, by Product Type, 2017 (US$ Mn)
2.4. Global PV Market, by Geography, 2017 (US$ Mn)
Chapter 3. Pneumococcal Vaccines (PV) Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global PV Market, by Key Players, 2017
Chapter 4. Global Pneumococcal Vaccines (PV) Market, by Vaccine Type, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Pneumococcal Conjugate Vaccine
4.3. Pneumococcal Polysaccharide Vaccine
Chapter 5. Global Pneumococcal Vaccines (PV) Market, by Product Type, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. 10-valent PCV
5.3. 13-valent PCV
5.4. 23-valent PPSV
5.5. Pipeline Analysis
5.5.1. Phase III Analysis
5.5.1.1. 15-valent PCV
5.5.1.2. 20-valent PCV
5.5.2. Tabular Representation of Phase I and Phase II Vaccines
Chapter 6. Global Pneumococcal Vaccines (PV) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. North America PV Market Analysis, 2016 – 2026
6.1.1. North America PV Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.1.2. North America PV Market, by Product Type, 2016 - 2026 (US$ Mn)
6.1.3. North America PV Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe PV Market Analysis, 2016 – 2026
6.2.1. Europe PV Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.2.2. Europe PV Market, by Product Type, 2016 - 2026 (US$ Mn)
6.2.3. Europe PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific PV Market Analysis, 2016 – 2026
6.3.1. Asia Pacific PV Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific PV Market, by Product Type, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America PV Market Analysis, 2016 – 2026
6.4.1. Latin America PV Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.4.2. Latin America PV Market, by Product Type, 2016 - 2026 (US$ Mn)
6.4.3. Latin America PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa PV Market, 2016 – 2026
6.5.1. Middle East & Africa PV Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.5.2. Middle East & Africa PV Market, by Product Type, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa PV Market, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa
Chapter 7. Company Profiles
7.1. Pfizer, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. GlaxoSmithKline PLC
7.3. Merck & Co., Inc.
Note :
Modification in the list of company profiles or scope of the study can be incorporated on request.
* PV - Pneumococcal Vaccines
TABLE 1 Global Pneumococcal Vaccines (PV) Market Portraiture
TABLE 2 Global Pneumococcal Vaccines Discovery Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 4 Pipeline Analysis: Phase I & II Vaccines
TABLE 5 Global PV Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 7 North America PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 8 North America PV Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 9 Europe PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 10 Europe PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 11 Europe PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 17 Latin America PV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East & Africa PV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East & Africa PV Market, by Product Type, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East & Africa PV Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 21 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Merck & Co., Inc..: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
FIG 1. Pneumococcal Vaccines (PV) Market: Research Methodology
FIG 2. PV Market Segmentation
FIG 3. Global PV Market, by Vaccine Type, 2017 (US$ Mn)
FIG 4. Global PV Market, by Product Type, 2017 (US$ Mn)
FIG 5. Global PV Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global PV Market, by Key Players, 2017
FIG 8. Global Pneumococcal Conjugate Vaccines (PCV) Market, 2016-2026 (US$ Mn)
FIG 9. Global Pneumococcal Polysaccharide Vaccines (PPSV) Market, 2016-2026(US$ Mn)
FIG 10. Global 10-valent PCV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 11. Global 13-valent PCV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 12. Global 23-valent PPSV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 13. Global 15-valent PCV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 14. Global 20-valent PCV Market in Pneumococcal Vaccines, 2016-2026(US$ Mn)
FIG 15. U.S. PV Market, 2016-2026 (US$ Mn)
FIG 16. Canada PV Market, 2016-2026 (US$ Mn)
FIG 17. U.K. PV Market, 2016-2026 (US$ Mn)
FIG 18. Germany PV Market, 2016-2026 (US$ Mn)
FIG 19. Rest of Europe PV Market, 2016-2026 (US$ Mn)
FIG 20. China PV Market, 2016-2026 (US$ Mn)
FIG 21. Japan PV Market, 2016-2026 (US$ Mn)
FIG 22. Rest of Asia Pacific PV Market, 2016-2026 (US$ Mn)
FIG 23. Brazil PV Market, 2016-2026 (US$ Mn)
FIG 24. Mexico PV Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Latin America PV Market, 2016-2026 (US$ Mn)
FIG 26. GCC PV Market, 2016-2026 (US$ Mn)
FIG 27. Rest of Middle East & Africa PV Market, 2016-2026 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)